ARK Innovation ETF vs Boston Scientific Corporation — how do they compare? ARK Innovation ETF trades at $81.38, while Boston Scientific Corporation trades at $51.07 (market cap $74.19B). The key difference: ARK Innovation ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| ARKK | BSX | |
|---|---|---|
52-Week High | $92.50 | $108.14 |
52-Week Low | $63.52 | $42.63 |
Market Cap | — | $74.19B |
Sector | — | Health |
Enterprise Value | — | $86.27B |
Trailing returns across standard periods
Latest headlines on both assets
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →